

Article

# Predicting the Potency of Anti-Alzheimer's Drug Combinations Using Machine Learning

Thomas J. Anastasio

Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA; tja@illinois.edu; Tel.: +1-217-244-2895

**Abstract:** Clinical trials of single drugs intended to slow the progression of Alzheimer's Disease (AD) have been notoriously unsuccessful. Combinations of repurposed drugs could provide effective treatments for AD. The challenge is to identify potentially effective combinations. To meet this challenge, machine learning (ML) was used to extract the knowledge from two leading AD databases, and then "the machine" predicted which combinations of the drugs in common between the two databases would be the most effective as treatments for AD. Specifically, three-layered artificial neural networks (ANNs) with compound, gated units in their internal layer were trained using ML to predict the cognitive scores of participants, separately in either database, given other data fields including age, demographic variables, comorbidities, and drugs taken. The predictions from the separately trained ANNs were statistically highly significantly correlated. The best drug combinations, jointly determined from both sets of predictions, were high in nonsteroidal anti-inflammatory drugs; anticoagulant, lipid-lowering, and antihypertensive drugs; and female hormones. The results suggest that the neurodegenerative processes that underlie AD and other dementias could be effectively treated using a combination of repurposed drugs. Predicted drug combinations could be evaluated in clinical trials.

**Keywords:** Alzheimer's disease; neurodegeneration; multifactorial disorder; polypharmacy; drug combination; drug repurposing; artificial intelligence; artificial neural network; machine learning



**Citation:** Anastasio, T.J. Predicting the Potency of Anti-Alzheimer's Drug Combinations Using Machine Learning. *Processes* **2021**, *9*, 264. <https://doi.org/10.3390/pr9020264>

Academic Editor: Alessandro Tonacci  
Received: 19 November 2020  
Accepted: 21 January 2021  
Published: 29 January 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Artificial intelligence (AI) and machine learning (ML) hold great promise for advancing biomedicine [1–3]. In Alzheimer's disease (AD), as in most other areas of biomedicine, AI and ML have been deployed mainly in automatic diagnosis on the basis of imaging data, augmented in some cases with biomarker or omics data, clinical findings, or demographics [4,5]. Accuracies in excess of 95% correct AD diagnosis are commonly reported. Despite the success in automatic diagnosis, the use of AI and ML for the purpose of drug discovery in AD is still an emerging area.

AI and ML have been combined with more traditional techniques (e.g., quantitative structure activity relationship, or QSAR) for the identification of new compounds potentially active against targets implicated in neurodegenerative diseases, including AD [6]. Although the overwhelming majority of these studies were focused on single targets, the development of compounds capable of binding multiple targets has become a "major goal" [6]. AI and ML have also been applied in "virtual screening" for novel compounds against specific targets. Such use against AD targets has been suggested, but here again the focus is on single drugs against single targets [7].

The repurposing of old drugs for treatment of neurodegenerative diseases is another emerging effort [8,9]. The main benefit of the repurposing approach is the prior approval for safety of the candidate drugs and the consequent accessibility "to academic institutions, government and research council programmes, charities and not-for-profit organizations", which complement "the work of pharmaceutical and biotechnology companies" and

substantially reduce “the time and cost involved in progressing the potential treatment into clinical trials” [9]. Drug candidates for AD repurposing have been identified on the basis of epidemiological and/or empirical (in vitro/in vivo) evidence, or by panels of experts. Though the emphasis of most repurposing efforts has been on single drugs, interest is growing in the AD community for using combinations of repurposed drugs, reflecting the now common understanding of AD as a multifactorial disorder [10–14]. The main challenge remains to identify the best candidates from among the many possible combinations of repurposed drugs.

The identification of potentially effective AD treatments is urgently needed. The development of treatments for slowing the progression of AD and other neurodegenerative disorders is lagging far behind the improvements in treatments for other major diseases [15–17]. Consequently, increasing numbers of people in developed countries are living long enough to become demented. No reasonable AD treatment approach should go unexplored. Considering the rapidity with which already approved and widely used drugs can be repurposed, the effort to identify potentially effective combinations of repurposed drugs for AD treatment should be given high priority.

AI and ML are uniquely well suited to address the challenge of identifying potentially effective combinations of repurposed drugs for AD treatment. They could be used to leverage the knowledge contained in AD databases to make the best attainable predictions as to which combinations of repurposed drugs could be used effectively to treat AD. Despite the availability of large databases on aging and dementia, no effort has yet been made to apply ML to the data they contain in order to predict effective combinations of repurposed drugs. This initial study is the first of its kind.

The goal of this project is to use ML to extract the knowledge contained in two leading AD databases, and use the extracted knowledge to identify drug combinations that could be effective in treating AD-associated neurodegeneration. The two AD datasets were obtained from the Rush Alzheimer’s Disease Center (RADC) and the National Alzheimer’s Coordinating Center (NACC). Both databases are highly regarded and used worldwide. Readers interested in epidemiological details and other database specifics are referred to the RADC and NACC websites (the relevant URLs are <https://www.radc.rush.edu/> for RADC and <https://www.alz.washington.edu/> for NACC).

NACC encompasses the data from the 29 Alzheimer’s disease centers (ADCs) that are funded by the National Institute on Aging of the National Institutes of Health of the United States [18,19]. RADC is an ADC but most of its dataset comes from the participants in the Religious Orders Study and the Rush Memory and Aging Project (ROSMAP) [20,21]. A small amount of legacy RADC data are included in NACC (less than 1.4% of total NACC data). All RADC data were removed from the NACC dataset for this study. The two datasets used for ML in this study are completely independent of each other (Supplementary Note S1).

Owing to vast increases in high-performance computing resources, artificial neural networks (ANNs) have become the state of the art in AI for generalizing from available data and making predictions. ANNs can be configured and trained in many different ways. This initial study employed an ANN as its generalizer/predictor, and its approach had two distinguishing features.

First, rather than simply choose one from among the many possible ANNs, a global optimization procedure was used to evaluate a large number of possible configurations to find which one would provide the best predictions (see Methods section). This process showed that the ANNs that were optimal for the ROSMAP or NACC datasets were essentially the same. Second, rather than combine all the available data to train one ANN, two ANNs having the same configuration were trained separately on the ROSMAP or NACC datasets and their predictions concerning the potency of many drug combinations were compared (see Results section). The strong correlation between the two sets of predictions increases confidence in the jointly determined best drug combinations.

## 2. Methods

Artificial neural networks (ANNs) are computational devices that are composed of many interconnected processing units. The units can be arranged in many different ways. In principle, any unit could be connected to any other unit, but in most ANNs, units are structurally organized. The units in many commonly used ANNs are organized into layers with an input layer, an output layer, and one or more internal layers that progress in order from the input to the output layer. Forward connections project forward, in the direction from the input to the output, and can connect any unit in a previous layer (e.g., input or lower-order internal) to any unit in a subsequent layer (e.g., higher-order internal or output). Conversely, recurrent connections project back, in the direction from the output to the input, and can connect any unit in a subsequent layer to any unit in a previous layer. Recurrent connections can also occur between units in the same layer.

The variables of an ANN are the weights of the connections between the units. The values of these connection weights are usually adjusted using some form of ML. The ML technique used to train ANNs in this study is a type of supervised learning, which requires a dataset composed of many input/desired-output examples. In supervised learning, an input is processed to form an output, and the actual output is compared to the desired output to form an error. The error is used to modify the weights of the connections between the units in the network, in such a way that the error between the actual and desired output for that input is reduced. Over many training cycles (i.e., many input/desired-output presentations), the error can be reduced substantially and the match between the actual and desired outputs can become quite close.

Most units in ANNs compute the sum of the weighted connections they receive from other units. The activation level of a linear unit is simply this weighted input sum. The activation level of a nonlinear unit is the weighted input sum after it is operated on by a nonlinear function (usually a sigmoidal function that bounds the weighted input sum in the range (0, 1) or  $(-1, +1)$ ). Such simple units are the most common. ANNs can sometimes contain more complex units, which themselves are composed of a set of interconnected simple units (see [22] for further background on ANNs).

The ANNs considered here had three layers: an input, an output, and one internal layer. Forward connections connected input to internal units and internal to output units. Linear units composed the input layer. Each input unit represented the value of an input variable, scaled into the range (0, 1). The output layer was composed of nonlinear units that computed the sum of their weighted connections from internal units and imposed a sigmoidal activation function on it, squashing it into the range (0, 1). The numbers of units in the input and output layers are fixed by the dataset on which the ANN is trained (see below and Figure 1). There is no limit on the number of internal layers, or on the number of internal units in each internal layer, of an ANN.

Compound units known as long short-term memory units (LSTMs) composed the internal layer. Several nonlinear units compose each LSTM, where some units act as gates that modulate the activations of other units [23,24] (Supplementary Note S2). The LSTMs in the ANNs considered here received forward connections from input units and recurrent connections from each other. LSTMs are so called because they have their own inner memory, mediated by an inner recurrent connection. The outer recurrent connections between LSTMs can enhance this memory. The recurrent connections (inner and/or outer) of a recurrently connected layer of LSTMs endows an ANN with considerable power to process information in time. If changes over time are useful for reproducing desired outputs given temporal sequences of inputs, then a three-layered ANN having a recurrently connected internal layer of LSTMs will exploit them.


The power and versatility of an ANN having a recurrently connected layer of LSTMs can be further appreciated by noting that each time step of processing in a recurrent network is equivalent to an additional internal layer in a feedforward network [22]. Thus, an ANN having a recurrently connected layer of LSTMs can subsume the processing capability of many types of simpler ANNs, including feedforward ANNs having multiple internal

layers, and feedforward or recurrent networks of simple units or of compound units with various types of inner gating. However, a given processing task may not require the full power of an ANN having a recurrently connected layer of LSTMs. The best configuration for a given application may be a simplification of this network type. A determination of the best configuration was a distinctive feature of this study (see below).

Recurrent LSTM networks can be trained using a supervised learning algorithm known as backpropagation through time (BPTT) [22,25]. BPTT draws temporal sequences of input/desired-output examples from the dataset at random (with replacement), and continues training the ANN over many iterations, thereby reducing the error over the dataset. The version of BPTT used here has three parameters: starting and ending learning rate and fixed momentum. The learning rate decreases from starting to ending as the training iterations proceed from first to last, and the momentum determines how much of the previous iteration's learning should be applied on the current iteration. These learning parameters will likely vary between ANNs having different configurations.

Once trained, the ANN not only can reproduce the desired outputs for the inputs in the dataset but can also generalize the knowledge it has extracted, and can predict the outputs for inputs on which it has not been trained. To assess generalizability, the dataset is divided into a training set (usually 75% of the dataset) and a testing set (the other 25%). Then the ANN is trained on the training set and tested on the testing set. The generalization error is the total error between the actual (predicted) and desired outputs over the testing set.

BPTT entails two sources of randomness: random initial connection weights and random presentation of input/desired-output sequences. Consequently, ANNs trained on the same dataset can vary in their outputs, and the best predictions are derived from the averaged outputs of many trained ANNs (around ten trained ANNs are usually considered sufficient) [26]. Generalizability, which is essentially the ability of an ANN to predict desired outputs over the testing set, is likewise best assessed by averaging the actual outputs of many retrained ANNs.



**Figure 1.** Drug combination potencies were predicted using trained artificial neural networks (ANNs) composed of simple and compound units. (A) The ANNs had three layers: input, internal, and output. All input units connected to all internal units, and all internal units connected to all output units. ANNs trained on the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) dataset had 113 input and 25 output units, while ANNs trained on the National Alzheimer's Coordinating Center (NACC) dataset had 101 input and 57 output units. Both ANNs had 80 internal units. (B) The internal units were compound units (CUs). Each CU had its own in, out, and gate unit. Both the in and the gate units of each CU received connections from all input-layer units. The gate unit modulated the activation of the CU in unit (i.e., gate unit output multiplies in unit output, signified as ●) before it was sent to the CU out unit. Each CU out unit connected to every output-layer unit.

The overall goal of this work was achieved in three steps. The first was to process the data contained in two AD databases into a form suitable for training ANNs using ML. The second step was to choose the best ANN configuration for this application. The third step was to use the best ANN to perform the computational drug-combination screens that provide the results of this study.

### 2.1. Processing the Data from Two AD Databases

The ROSMAP and NACC databases have similar fields which included, for each participant, age at visit, demographics (sex, race, etc.), tobacco and alcohol use, comorbidities (cancer, stroke, etc.), drugs taken, and the results over a battery of cognitive tests (e.g., number of different animal types recalled in one minute, or number of facts remembered from a text excerpt). The data in these fields were arranged into input/desired-output pairs, where the desired outputs were the cognitive test results and the inputs were the values for all the other fields for each visit. The number of desired outputs (cognitive scores) and inputs (all fields except cognitive scores) were 25 and 113 for ROSMAP, and 57 and 101 for NACC, respectively (Figure 1).

AD is a disease process that proceeds in time. Therefore, age is a key variable, and changes with age of other input variables could also affect cognitive scores. The temporal sequences of age and other inputs could contain information useful for reproducing cognitive scores from input data. The form of ANN chosen for this study, a three-layered ANN with a recurrently connected internal layer of LSTMs, exploits information contained in temporal sequences of inputs if doing so contributes to the reproduction of desired outputs. For this reason, all of the input/desired-output pairs were arranged into temporal sequences for each participant. Specifically, the input/desired-output pairs for each participant were ordered by their age at each visit into an age-advancing sequence. On each training iteration, the ANN was presented with the age-advancing sequence for a randomly chosen participant. The input/desired-output pairs in that participant's sequence were presented one at a time, but in order of age at visit so that temporal information was preserved. In this way, any information contained in the temporal sequences themselves would be exploited by the ANN. The ANN was trained only on age-advancing sequences of at least ten ages (Supplementary Note S1).

Both the ROSMAP and NACC databases had missing data. Overall, 3% and 39% of values were missing from the ROSMAP and NACC databases, respectively. Missing values were spread over the dataset such that 87% and 100% of input/desired-output examples (i.e., pairs) had at least one missing value in the ROSMAP and NACC datasets, respectively. In order to ensure that an adequate number of input/desired-output pairs were available for training, workarounds of missing data were implemented.

Missing input data were replaced by the average of the data for that field. This is consistent with the maximum-entropy approach to missing data that is standard in ML applications [27]. Missing desired-output data were left blank, but during training all errors associated with missing desired-output data were set to zero. Because connection weight modifications in BPTT are based on error, no weight modifications were made due to missing desired-output data. While the weights onto output units representing absent desired-output values were not trained, all other network connection weights were trained on the basis of the desired-output values that were present in any given input/desired-output example.

Redundant database fields were removed. Ideally, the values assigned to an input or desired output should increase monotonically with the variable it represents, but database field codes can deviate widely from that simple relationship. For example, the scoring for frontotemporal dementia in the NACC database is 0, 1, or 8 for dementia that is not frontotemporal, dementia that is frontotemporal, or no dementia at all. To make it monotonic, the frontotemporal dementia score was rearranged to 0, 1, or 2 for no dementia, dementia that is not frontotemporal, and dementia that is frontotemporal, respectively. Specific input or desired-output values were rearranged or reassigned, when necessary,

to bring them all into a monotonically increasing regime. Finally, the input and desired-output data (except for missing desired-output data, which simply remained missing) were normalized to (0, 1).

## 2.2. Choosing the Best ANN Configuration

The combination of ANN features and ML parameters providing the best generalizability was determined using a genetic algorithm (GA) [28,29] (Supplementary Note S3). Because of the randomness inherent in GAs, the best solution represents the consensus over multiple GA runs. Ten GA runs were performed separately for the ROSMAP and NACC datasets, producing twenty runs altogether (the computational intensity of GAs precluded larger numbers of GA runs). The GA results were similar between the two datasets and the consensus was obvious (Supplementary Table S1).

Using GA optimization, the best (i.e., consensus) ANN for this application lacked recurrent connections both inside and between LSTMs. This indicates that memory capability, and its attendant ability to process sequences temporally, did not improve ANN generalizability. The reason, probably, is because age, which provides a direct and accurate measure of time, was included as an input so the ANN did not need to infer time through temporal processing. Furthermore, the best ANN for this application had LSTMs simplified to a single gating interaction. Because the internal units in the best network were such drastic simplifications of LSTMs, they are simply referred to as compound units (CUs). The best (i.e., consensus) ANN is diagrammed in Figure 1.

The use of gating is common in ANN applications in which different internal units learn to specialize for different subsets of the dataset [30]. The fact that the consensus ANN employed gated units suggests that such specialization improved generalizability in this application. The consensus ANN had about 80 compound, gated units in its internal layer, and its optimal ML parameters were 0.0600, 0.0006, and 0.0002 for starting and ending learning rate and fixed momentum, respectively.

## 2.3. Performing the Computational Drug-Combination Screens


Consensus ANNs were trained on the ROSMAP or NACC datasets separately because their cohorts differ markedly (community versus clinical), and because their corresponding databases have many structural differences (e.g., different numbers and kinds of cognitive tests). Therefore, the datasets cannot be merged without making many unsupportable assumptions. The trained ANNs were used to screen all possible combinations of the drugs in common between the two databases.

The drugs in both databases were listed in drug categories rather than as specific drugs. The categories in common were: nonsteroidal anti-inflammatory drugs (NSAIDs, mainly cyclooxygenase-2 (COX2) inhibitors and aspirin); angiotensin converting enzyme (ACE) inhibitors; angiotensin II receptor blockers (ARBs); calcium channel blockers; beta blockers; diuretics; vasodilators; anticoagulants; lipid-lowering drugs; antidiabetics; estrogen or progestin; anti-adrenergics; antidepressants; antipsychotics; anxiolytics; anti-Parkinson's drugs; and anti-Alzheimer's drugs (mainly acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor blockers). There are 131,072 combinations of these 17 drug categories, and consensus ANNs, trained on either the ROSMAP or NACC datasets, were tested on every combination. This constituted two, separate computational screens (ROSMAP or NACC) over all 100,000+ drug combinations.

The inputs to the ANNs were all data fields other than cognitive scores. They included demographics, tobacco and alcohol use, and comorbidities as well as drugs taken. Valid comparison of the predicted potencies of different drug combinations required testing each drug combination using a standard input, in which all inputs besides drugs were the same. The standard input was based on an age-advancing sequence of 100 (non-integer, real number) ages from 50 to 110 years, which encompasses the age range of the participants in the two databases. All of the other inputs, separately for either database, were resampled

to conform to this sequence by computing a value that is representative of each input field at each age in the standard sequence (Supplementary Note S4).

Then a consensus ANN had its weights randomized and was trained on a full dataset (either ROSMAP or NACC), and the cognitive scores predicted by the trained ANN for each drug combination at each age in the standard age-advancing sequence were found. Note that each output unit (25 for ROSMAP or 57 for NACC) represents the ANN's prediction for one cognitive test. A combined cognitive score for each age in the standard sequence (a single number for each age) can be computed by averaging over the scores of the different cognitive tests, each represented by an individual output unit (an average over 25 output units for ROSMAP or 57 output units for NACC). For illustrative purposes, the combined cognitive scores as predicted by one ANN for many representative (not all 100,000+) drug combinations versus age are shown in Figure 2.




**Figure 2.** The combined cognitive scores as predicted by a single ANN for each age in the age-advancing sequence for 65 representative drug combinations (every 2000th combination selected from the full set of 131,072 combinations of 17 drugs). Each output unit represented the score of a different cognitive test, so the combined cognitive score was the average over the output unit activations. The combined cognitive score in the no-drug case is shown as a heavy red line. These results show that a substantial proportion of drug combinations are predicted to improve cognitive performance above the no-drug case in a cohort of elderly participants. This ANN was trained on the ROSMAP dataset. The results for ANNs trained on the NACC dataset are similar (Supplementary Figure S1).

To improve the accuracy of the prediction (see Methods section), the processes of randomization, retraining, and predicting were repeated 100 times for either dataset, and the predicted scores for each cognitive test, each represented by an individual output unit, were averaged over the 100 ANNs. Then the combined cognitive score was computed by averaging over the averaged predicted outputs. Thus, the combined cognitive scores actually used to compute drug-combination predicted potencies were based not on one, but on the average of 100 retrained consensus ANNs.

To obtain a single number for the predicted potency of each drug combination, the differences between the combined cognitive scores predicted for that drug combination and the cognitive scores predicted for no drugs at all ages in the age-advancing sequence were averaged. Briefly summarized, the drug-combination predicted potencies are the averaged (differences) over 100 ages, of averaged predicted scores over a number of different cognitive tests (25 for ROSMAP or 57 for NACC), each represented by the averaged output unit activations of 100 retrained consensus ANNs. Thus, predicted potencies are relative measures where the reference values are the no-drug predictions. The results of this study are reported in terms of the potency of each specific drug combination, as predicted from consensus ANNs trained either on the ROSMAP or NACC datasets. For brevity, these separately trained ANN predictions will be referred to as ROSMAP predictions or NACC predictions.

### 3. Results

The results presented in Figure 2 show that the combined cognitive scores predicted from ANNs can be greater for many drug combinations than for no drugs. The scores shown in Figure 2 were predicted from an ANN trained on the ROSMAP dataset; those predicted from an ANN trained on the NACC dataset are similar (Supplementary Figure S1). The ROSMAP or NACC predictions could be taken at face value, but our confidence in the two sets of predictions would be strengthened if they agreed. Figure 3A shows that they do agree (see also Supplementary Figure S2).



**Figure 3.** Predicting potent drug combinations jointly from ANNs trained separately on the ROSMAP or NACC datasets for the 131,072 combinations of 17 drug categories. (A) The potencies predicted by ANNs trained on the ROSMAP and NACC datasets are highly statistically significantly correlated. Each blue dot represents one drug combination, located by its ROSMAP and NACC predicted potency ( $r$  is the correlation coefficient, and  $p$  is the probability that the correlation occurred by chance). (B) All 131,072 drug combinations are ranked according to predicted potency (top is highest) and displayed as a heat map (yellow, drug present; blue, drug absent). Each column represents one of the 17 drug categories. The most potent drug combinations include anti-Alzheimer's drugs (shown in the last column).

#### 3.1. Correlating ROSMAP and NACC Drug-Combination Predicted Potencies


The highly statistically significant correlation between the ROSMAP and NACC predictions motivates joint predictions based on both datasets together rather than on

either one alone. Drug combination potencies can be predicted jointly from the ROSMAP and NACC predictions in terms of the values of the projections of the drug combination points onto the regression line. All 131,072 combinations of the 17 drug categories, rank ordered according to their jointly predicted potency, are shown Figure 3B.

From Figure 3B it seems that the benefit of a drug combination depends on whether or not it includes anti-Alzheimer's drugs, whose primary effect is to improve the cognitive ability of AD sufferers. Other drugs that affect mood and/or cognitive ability, especially antipsychotic drugs, also seem to improve the combined cognitive score (Supplementary Figure S3). It is possible that drugs that act on the cognitive and/or psychological level and that improve cognition, either directly or by improving mood or behavioral control, may mask the neuroprotective effects of other drugs.

### 3.2. Restricting the Drug-Combination Screens


Of interest here are drug combinations that may treat neurodegeneration or slow its progress. To uncover such potentially potent treatments, the drug-combination screen was repeated following the removal of all drugs that act mainly on the cognitive and/or psychological level. Those included the anti-Alzheimer's and anti-Parkinson's drugs as well as the anti-adrenergics, antidepressants, antipsychotics, and anxiolytics. This left drugs in eleven categories. The ROSMAP and NACC predictions for their 2048 combinations were also highly significantly correlated, as shown in Figure 4A.



**Figure 4.** Predicting potent drug combinations jointly from ANNs trained on the ROSMAP or NACC datasets for the 2048 combinations of the 11 drug categories that do not target cognitive ability or mood. (A) The potencies predicted by ANNs trained on the ROSMAP or NACC datasets are highly significantly correlated. (B) The top ten drug combinations are ranked according to predicted potency (1 is highest) and displayed as a heat map (yellow, drug present; blue, drug absent). Each column represents one of the 11 drug categories. The top ten combinations include nonsteroidal anti-inflammatory (NSAID), antihypertensive, anticoagulant, and lipid-lowering drugs, as well as estrogen/progestin.

As shown in Figure 4B, the top ten combinations of these eleven drug categories, jointly determined from the ROSMAP and NACC predictions, all included NSAID, anticoagulant, and lipid-lowering drugs, as well as the female hormones estrogen and/or progestin. The top nine also included one or more of these antihypertensive drugs: angiotensin II receptor blockers, calcium channel blockers, beta blockers, and diuretics.

While many elderly women and some elderly men take estrogen or progestin medicinally, taking those hormones would not be appropriate for all AD sufferers. For that reason, the drug-combination screen was repeated following the removal of estrogen/progestin, as well as all drugs that act mainly on the cognitive and/or psychological level. This left drugs in ten categories. The ROSMAP and NACC predictions for their 1024 combinations were also highly significantly correlated, as shown in Figure 5A.



**Figure 5.** Predicting potent drug combinations jointly from ANNs trained on the ROSMAP or NACC datasets for the 1024 combinations of the 10 drug categories that do not include estrogen/progestin or target cognitive ability or mood. (A) The potencies predicted by ANNs trained on the ROSMAP or NACC datasets are highly significantly correlated. The ten best drug combinations as determined jointly in terms of linear regression, sum of potency, or sum of rank of potency as predicted by ANNs trained separately on the ROSMAP or NACC datasets are shown as green line segments, magenta o's, or cyan x's, respectively. (B) The top ten drug combinations are ranked according to linear regression (1 is highest) and displayed as a heat map (yellow, drug present; blue, drug absent). Each column represents one of the 10 drug categories. The top ten combinations include NSAID, antihypertensive, anticoagulant, and lipid-lowering drugs.

As shown in Figure 5B, the top ten combinations of these ten drug categories, jointly determined from the ROSMAP and NACC predictions, are similar to those that included estrogen/progestin. They all included NSAID, anticoagulant, and lipid-lowering drugs. Additionally, the top ten combinations all included one or more drugs from all of the antihypertensive categories: ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta blockers, and diuretics.

### 3.3. Alternative Rankings of the Best Combinations


The simplest way to rank the drug combinations is separately in terms of the ROSMAP or NACC predictions alone. The top ten drug combinations determined from ROSMAP or NACC predictions alone are similar to the jointly determined combinations in that they all include NSAID and lipid-lowering drugs, and most also include anticoagulant and antihypertensive drugs (Supplementary Figure S4). Owing to the highly significant correlation between the ROSMAP and NACC predictions, the uncertainty associated with rankings based on ROSMAP or NACC predictions alone can be reduced by rankings that consider both sets of predictions together.

In previous sections, the joint determination was made in terms of the projections of the ROSMAP and NACC prediction points onto the line resulting from the regression of the NACC predictions onto the ROSMAP predictions (NACC predictions as a function of ROSMAP predictions, or NACC(ROSMAP)) (Figures 3A, 4A and 5A). Because correlation

is symmetric, rankings based on NACC(ROSMAP) or ROSMAP(NACC) (ROSMAP predictions as a function of NACC predictions) regressions are identical (Supplementary Figure S5). Joint rankings in terms of linear regression proceed most naturally from correlation analysis.

Other methods of jointly determining drug combination potency include ranking the sums of the ROSMAP and NACC predictions for each combination, or ranking the sums of the rankings of the combinations based on the ROSMAP or NACC predictions alone. The sets of ten-best drug combinations determined according to the sum or rank-sum methods overlap with the set determined according to linear regression, and encompass the points at the top-right of the scatter plot, as shown in Figure 5A.

As shown in Figure 6, the top ten combinations of the ten drug categories that exclude estrogen/progestin and the drugs that act mainly on the cognitive and/or psychological level, jointly determined using the sum, rank-sum, or linear regression methods, are similar. They all included NSAID, anticoagulant, and lipid-lowering drugs. Additionally, most of the top ten combinations included multiple antihypertensive drugs. The main difference was that the sum and rank-sum methods excluded ACE inhibitors while the linear regression method included them.



**Figure 6.** Different joint ranking methods yield similar orderings of drug combinations. The ten best combinations of the ten drug categories that do not include estrogen/progestin or target cognitive ability or mood, as predicted jointly by ANNs trained separately on the ROSMAP or NACC datasets, are rank ordered in three different ways and displayed as heat maps (yellow, drug present; blue, drug absent). Each column represents one of the 10 drug categories (category names are abbreviated). The top ten combinations all include NSAID, antihypertensive, anticoagulant, and lipid-lowering drugs, whether the ranking is based on the sum of separately predicted potencies (ROSMAP + NACC SUM), the sum of the ranks of separately predicted potencies (ROSMAP + NACC RANK SUM), or the projections onto the regression line giving NACC potency as a function of ROSMAP potency (NACC(ROSMAP)). Concerning the third method, note that the NACC(ROSMAP) and ROSMAP(NACC) (ROSMAP potency as a function of NACC potency) regressions yield identical orderings of drug-combination predicted potency (Supplementary Figure S5).

#### 4. Discussion

The ten-best combinations of the eleven drugs that excluded drugs acting mainly on the cognitive and/or psychological level included NSAID, anticoagulant, lipid-lowering, and antihypertensive drugs, as well as estrogen/progestin. Drugs from all of these categories have been shown to reduce AD risk; however they all show disappointing results when used singly in clinical trials [31–43]. The use of combinations of these and other drugs remains an attractive option [10–14].

However they are ranked, the ten best combinations of the ten or eleven drugs that excluded those that target cognition or mood directly, jointly determined from the ROSMAP and NACC predictions, included three to eight drugs. This finding supports the general idea that multiple drugs (including hormones) may indeed be effectively used to treat neurodegeneration, which is a multifactorial disease process [10–14]. The ten best combinations are not random but tend to include drugs from the same categories: NSAID, anticoagulant, lipid-lowering, and antihypertensive drugs, as well as estrogen/progestin.

One possible interpretation of the results is that elderly individuals who take these drugs have better cognitive function than those who do not, because the conditions these drugs treat are associated with better cognitive function. This interpretation is ruled out by statistical analysis of the ROSMAP and NACC datasets showing that comorbidities, singly or in combination, do not improve cognitive function (Supplementary Figures S6 and S7).

It is interesting that the predicted cognitive scores for many drug combinations are higher than those for the no-drug case. This can be seen in Figure 2 with reference to the no-drug prediction (red line), and in Figures 3A, 4A and 5A for all points with ROSMAP and NACC predictions higher than zero (the no-drug prediction). This result implies that certain drug combinations may improve cognitive function beyond what would be expected if each drug merely normalized its primary treatment target (e.g., lipid-lowering and antihypertensive drugs that normalize lipid levels and blood pressure, respectively). Such improvements beyond the no-drug condition could result from synergies in primary and/or secondary drug effects. For example, certain NSAIDs (mainly COX2 inhibitors) not only reduce inflammation but also reduce amyloid- $\beta$  production [44–46], while certain antihypertensive drugs also have anti-inflammatory properties [47–49].

Drugs that act mainly on the cognitive or psychological level were excluded from most analyses because they could mask the effects of other drugs, and combinations thereof, that might improve cognitive function by slowing down an underlying process of neurodegeneration. The leading cases in point were the anti-Alzheimer's drugs (mainly acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor blockers), which practically dichotomized the entire set of 100,000+ drug combination predictions into those with and those without anti-Alzheimer's drugs (Figure 3B). Other drugs that act on the cognitive or psychological level, mainly antipsychotics and antidepressants, may similarly mask the potential effects of other drugs on neurodegeneration (Supplementary Figure S3B). Anti-Alzheimer's drug use was 6% and 27% in the ROSMAP and NACC datasets, respectively, and antidepressant and antipsychotic drugs were used more often when participants also used anti-Alzheimer's drugs. Usage of other drugs was about the same whether or not participants also used anti-Alzheimer's drugs (Supplementary Figure S8).

The exclusion of drugs that act mainly on the cognitive or psychological level in no way implies that those drugs would not also slow down the neurodegenerative process, or would not synergize with other drugs that do. Though predictions were derived for combinations of subsets of the 17 drug categories in common between the ROSMAP and NACC databases (i.e., subsets that excluded drugs that target cognition or mood), the ANNs were trained on input patterns that included all 17 categories. Thus, any synergies present in the datasets between the drugs in the subsets (i.e., NSAID, anticoagulant, lipid-lowering, and antihypertensive drugs, as well as estrogen/progestin) and drugs that act mainly on the cognitive or psychological level (i.e., anti-Alzheimer's and anti-Parkinson's drugs as well as anti-adrenergics, antidepressants, antipsychotics, and anxiolytics) would have been learned by the ANNs and factored into all predictions.

The drugs appearing in the ten best combinations in this study overlap with those in a previous study in which ML was used to train a computational model of brain inflammation [50]. Model predictions of drug-combination efficacy were significantly correlated with the cognitive benefits of the same drug combinations as determined from the ROSMAP dataset. The ten best combinations from the previous study also included NSAIDs (COX2 inhibitors and aspirin) as well as antihypertensive drugs (ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, and beta blockers). Earlier computational studies of potential anti-Alzheimer's drug interactions were based on process-driven models, rather than on data-driven models as trained by ML. Those models suggested that NSAIDs could be effectively combined with antidiabetic drugs or estrogen as anti-Alzheimer's therapies [51,52]. The drug categories in the previous studies were not the same as in this study. That discrepancy limits the value of directly comparing their results.

All drugs in the computational combination screens in this study are approved. Many elderly people already take some of the drugs included in the ten best combinations. Where not contraindicated, other drugs could be added to their regimens to complete some of the predicted combinations, for the purpose of conducting controlled clinical trials to test them. The most promising candidates for testing include combinations of NSAID (COX2 inhibitors and aspirin), anticoagulant, and lipid-lowering drugs along with antihypertensive drugs such as angiotensin II receptor, calcium channel, or beta blockers, or ACE inhibitors. Combinations of NSAID, anticoagulant, and lipid-lowering drugs that also include more than one antihypertensive drug and, where not contraindicated, estrogen/progestin would be of particular interest.

For simplicity in this initial effort, the trained ANNs were used to predict the efficacy of drug combinations given a representative or "standard" patient (Supplementary Note S4), but they could be used alternatively to predict the efficacy of drug combinations given patients with specific demographic, comorbid, and other characteristics (there are tens of thousands of such combinations given the various ROSMAP or NACC input fields). For example, the ANNs could be used to predict the efficacy of all combinations of any set of drugs in common between the ROSMAP and NACC databases, including certain antihypertensive drugs, in elderly Hispanic women who neither smoke tobacco nor drink alcohol, and who are diabetic and take diabetes medication as well as a statin, but who are not hypertensive. No retraining would be required to make predictions concerning patients with any set of existing database characteristics. Retraining ANNs on augmented datasets that include additional input fields as they become available, such as genetic variants, would allow even finer tuning of predictions for specific subclasses of patients.

The current study has two major limitations. First, the drugs in the databases are not identified individually but by category. Many categories include drugs of different classes, which may affect neurodegeneration in different ways. Second, the ideal desired endpoints for the clinical trials would be reductions in biomarkers of neurodegeneration rather than improvements in cognitive ability, but the databases so far exclude biomarkers. AIs trained via ML on large datasets from databases that identify drugs individually, and that include biomarkers of neurodegeneration, could be used to make better predictions concerning combinations of repurposed drugs that would be effective in treating AD specifically and neurodegeneration more generally.

**Supplementary Materials:** The following are available online at <https://www.mdpi.com/2227-9717/9/2/264/s1>, Table S1: Optimizing ANN Configuration. Figure S1: NACC Predictions from a Single ANN. Figure S2: Regressing ROSMAP on NACC Predictions. Figure S3: Ranking non-AD Drug Combinations. Figure S4: Ranking ROSMAP or NACC Predictions Alone. Figure S5: NACC(ROSMAP) and ROSMAP(NACC) Orderings. Figure S6: ROSMAP Comorbidities and Cognitive Function. Figure S7: NACC Comorbidities and Cognitive Function. Figure S8: Drug Usage in ROSMAP and NACC. Note S1: The RADC and NACC Databases. Note S2: Long Short-term Memory Units. Note S3: Genetic Algorithms. Note S4: Standard Input Signal Processing.

**Funding:** A grant from the Alzheimer’s Disease Research Fund, administered by the Illinois Department of Public Health (IDPH), supported this research. The IDPH was not involved in any phase of the project.

**Acknowledgments:** Access to data was provided by the Rush Alzheimer’s Disease Center (RADC) of the Rush University Medical Center in Chicago, Illinois. The data provided by RADC come from the participants in the Religious Orders Study and the Rush Memory and Aging Project (ROSMAP). ROSMAP is supported by National Institute on Aging (NIA), of the National Institutes of Health grants P30AG10161, R01AG15819, and R01AG17917, and by the Illinois Department of Public Health. Access to data was also provided by the National Alzheimer’s Coordinating Center (NACC). The NACC database is funded by NIA Grant U01 AG016976. NACC data are contributed by NIA-funded Alzheimer’s Disease Centers: P30 AG019610 (Principal Investigator (PI) Eric Reiman), P30 AG013846 (PI Neil Kowall), P30 AG062428-01 (PI James Leverenz) P50 AG008702 (PI Scott Small), P50 AG025688 (PI Allan Levey), P50 AG047266 (PI Todd Golde), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert), P30 AG062421-01 (PI Bradley Hyman), P30 AG062422-01 (PI Ronald Petersen), P50 AG005138 (PI Mary Sano), P30 AG008051 (PI Thomas Wisniewski), P30 AG013854 (PI Robert Vassar), P30 AG008017 (PI Jeffrey Kaye), P30 AG010161 (PI David Bennett), P50 AG047366 (PI Victor Henderson), P30 AG010129 (PI Charles DeCarli), P50 AG016573 (PI Frank LaFerla), P30 AG062429-01 (PI James Brewer), P50 AG023501 (PI Bruce Miller), P30 AG035982 (PI Russell Swerdlow), P30 AG028383 (PI Linda Van Eldik), P30 AG053760 (PI Henry Paulson), P30 AG010124 (PI John Trojanowski), P50 AG005133 (PI Oscar Lopez), P50 AG005142 (PI Helena Chui), P30 AG012300 (PI Roger Rosenberg), P30 AG049638 (PI Suzanne Craft), P50 AG005136 (PI Thomas Grabowski), P30 AG062715-01 (PI Sanjay Asthana), P50 AG005681 (PI John Morris), and P50 AG047270 (PI Stephen Strittmatter).

**Conflicts of Interest:** The author declares no conflict of interest.

## References

1. Cao, C.; Liu, F.; Tan, H.; Song, D.; Shu, W.; Li, W.; Zhou, Y.; Bo, X.; Xie, Z. Deep learning and its applications in biomedicine. *Genom. Proteom. Bioinform.* **2018**, *16*, 17–32. [[CrossRef](#)] [[PubMed](#)]
2. Ching, T.; Himmelstein, D.S.; Beaulieu-Jones, B.K.; Kalinin, A.A.; Do, B.T.; Way, G.P.; Ferrero, E.; Agapow, P.-M.; Zietz, M.; Hoffman, M.M.; et al. Opportunities and obstacles for deep learning in biology and medicine. *J. R. Soc. Interface* **2018**, *15*, 20170387. [[CrossRef](#)] [[PubMed](#)]
3. Filipp, F.V. Opportunities for artificial intelligence in advancing precision medicine. *Curr. Genet. Med. Rep.* **2019**, *7*, 208–213. [[CrossRef](#)] [[PubMed](#)]
4. Jo, T.; Nho, K.; Saykin, A.J. Deep learning in Alzheimer’s disease: Diagnostic classification and prognostic prediction using neuroimaging data. *Front. Aging Neurosci.* **2019**, *11*, 220. [[CrossRef](#)] [[PubMed](#)]
5. Ebrahimiaghnavieh, M.A.; Luo, S.; Chiong, R. Deep learning to detect Alzheimer’s disease from neuroimaging: A systematic literature review. *Comp. Methods Progr. Biomed.* **2020**, *187*, 105242. [[CrossRef](#)]
6. Makhouri, F.R.; Ghasemi, J.B. *In silico* studies in drug research against neurodegenerative diseases. *Curr. Neuropharmacol.* **2018**, *16*, 664–725. [[CrossRef](#)]
7. Carpenter, K.A.; Huang, X. Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: A review. *Curr. Pharm. Des.* **2018**, *24*, 3347–3358. [[CrossRef](#)]
8. Singh, R.K. Recent trends in the management of Alzheimer’s disease: Current therapeutic options and drug repurposing approaches. *Curr. Neuropharmacol.* **2020**, *18*, 868–882. [[CrossRef](#)]
9. Ballard, C.; Aarsland, D.; Cummings, J.; O’Brien, J.; Mills, R.; Molinuevo, J.L.; Fladby, T.; Williams, G.; Doherty, P.; Corbett, A.; et al. Drug repositioning and repurposing for Alzheimer disease. *Nat. Rev. Neurol.* **2020**, *16*, 661–673. [[CrossRef](#)]
10. Perry, D.; Sperling, R.; Katz, R.; Berry, D.; Dilts, D.; Hanna, D.; Salloway, S.; Trojanowski, J.Q.; Bountra, C.; Krams, M.; et al. Building a roadmap for developing combination therapies for Alzheimer’s disease. *Expert Rev. Neurother.* **2015**, *15*, 327–333. [[CrossRef](#)]
11. Hendrix, J.A.; Bateman, R.J.; Brashear, H.R.; Dugganb, C.; Carrillo, M.C.; Bain, L.J.; DeMattos, R.; Katz, R.G.; Ostrowitzki, S.; Siemers, E.; et al. Challenges, solutions, and recommendations for Alzheimer’s disease combination therapy. *Alzheimers Dement.* **2016**, *12*, 623–630. [[CrossRef](#)] [[PubMed](#)]
12. Bachurin, S.O.; Bovina, E.V.; Ustyugov, A.A. Drugs in clinical trials for Alzheimer’s disease: The major trends. *Med. Res. Rev.* **2017**, *37*, 1186–1225. [[CrossRef](#)] [[PubMed](#)]
13. Shoaib, M.; Kamal, M.A.; Rizvi, S.M.D. Repurposed drugs as potential therapeutic candidates for the management of Alzheimer’s disease. *Curr. Drug Metab.* **2017**, *18*, 842–852. [[CrossRef](#)]
14. Ihara, M.; Saito, S. Drug repositioning for Alzheimer’s disease: Finding hidden clues in old drugs [published online ahead of print, Mar 3]. *J. Alzheimers Dis.* **2020**. [[CrossRef](#)] [[PubMed](#)]

15. Schneider, L.S.; Mangialasche, F.; Andreasen, N.; Feldman, H.; Giacobini, E.; Jones, R.; Mantua, V.; Mecocci, P.; Pani, L.; Winblad, B.; et al. Clinical trials and late-stage drug development for Alzheimer's disease: An appraisal from 1984 to 2014. *J. Int. Med.* **2014**, *275*, 251–283. [[CrossRef](#)]
16. Cummings, J.L.; Morstorf, T.; Zhong, K. Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. *Alzheimers Res. Ther.* **2014**, *6*, 37–44. [[CrossRef](#)]
17. Yaari, R.; Hake, A. Alzheimer's disease clinical trials: Past failures and future opportunities. *Clin. Investig.* **2015**, *5*, 297–309. [[CrossRef](#)]
18. Beekly, D.L.; Ramos, E.M.; Lee, W.W.; Deitrich, W.; Jacka, M.E.; Wu, J.; Hubbard, J.L.; Koepsell, T.D.; Morris, J.C.; Kukull, W.A. The National Alzheimer's Coordinating Center (NACC) database: The Uniform Data Set. *Alzheimer Dis. Assoc. Disord.* **2007**, *21*, 249–258. [[CrossRef](#)]
19. Besser, L.; Kukull, W.; Knopman, D.S.; Chui, H.; Galasko, D.; Weintraub, S.; Jicha, G.; Carlsson, C.; Burns, J.; Quinn, J.; et al. Version 3 of the National Alzheimer's Coordinating Center's uniform data set. *Alzheimer Dis. Assoc. Disord.* **2018**, *32*, 351–358. [[CrossRef](#)]
20. Bennett, D.A.; Schneider, J.A.; Buchman, A.S.; Barnes, L.L.; Boyle, P.A.; Wilson, R.S. Overview and findings from the Rush Memory and Aging Project. *Curr. Alzheimer Res.* **2012**, *9*, 646–663. [[CrossRef](#)]
21. Bennett, D.A.; Buchman, A.S.; Boyle, P.A.; Barnes, L.L.; Wilson, R.S.; Schneider, J.A. Religious Orders Study and Rush Memory and Aging Project. *J. Alzheimers Dis.* **2018**, *64*, S161–S189. [[CrossRef](#)]
22. Rumelhart, D.E.; McClelland, J.L.; PDP Research Group. *Parallel Distributed Processing: Explorations in the Microstructure of Cognition. Foundations*; MIT Press: Cambridge, UK, 1986.
23. Hochreiter, S.; Schmidhuber, J. Long short-term memory. *Neural Comp.* **1997**, *9*, 1735–1780. [[CrossRef](#)] [[PubMed](#)]
24. Greff, K.; Srivastava, R.K.; Koutník, J.; Steunebrink, B.R.; Schmidhuber, J. LSTM: A search space odyssey. *IEEE Trans. Neur. Net. Lear.* **2016**, *28*, 2222–2232. [[CrossRef](#)] [[PubMed](#)]
25. Werbos, P.J. Backpropagation through time: What it does and how to do it. *Proc. IEEE* **1990**, *78*, 1550–1560. [[CrossRef](#)]
26. Perrone, M.P.; Cooper, L.N. When networks disagree: Ensemble methods for hybrid neural networks. In *How We Learn, How We Remember: Toward an Understanding of Brain and Neural Systems*; Selected Papers of Leon N Cooper; Cooper, L.N., Ed.; World Scientific: Singapore, 1995; pp. 342–358.
27. Huang, B.; Sallab-Aouissi, A. Maximum entropy density estimation with incomplete presence-only data. *JMLR* **2009**, *5*, 240–247.
28. Holland, J.H. *Adaptation in Natural and Artificial Systems: An. Introductory Analysis with Applications to Biology, Control., and Artificial Intelligence*; MIT Press: Cambridge, UK, 1992.
29. Goldberg, D.E. *Genetic Algorithms in Search, Optimization, and Machine Learning*; Addison-Wesley: Reading, PA, USA, 1989.
30. Jacobs, R.A.; Jordan, M.I.; Nowlan, S.J.; Hinton, G.E. Adaptive mixtures of local experts. *Neural Comput.* **1991**, *3*, 79–87. [[CrossRef](#)]
31. Wang, J.; Tan, L.; Wang, H.F.; Tan, C.C.; Meng, X.F.; Wang, C.; Tang, S.W.; Yu, J.T. Anti-inflammatory drugs and risk of Alzheimer's disease: An updated systematic review and meta-analysis. *J. Alzheimers Dis.* **2015**, *44*, 385–396. [[CrossRef](#)]
32. Zhang, C.; Wang, Y.; Wang, D.; Zhang, J.; Zhang, F. NSAID Exposure and risk of Alzheimer's disease: An updated meta-analysis from cohort studies. *Front. Aging Neurosci.* **2018**, *10*, 83. [[CrossRef](#)]
33. Ruiz Vargas, E.; Sposato, L.A.; Lee, S.A.W.; Hachinski, V.; Cipriano, L.E. Anticoagulation therapy for atrial fibrillation in patients with Alzheimer's disease. *Stroke* **2018**, *49*, 2844–2850. [[CrossRef](#)]
34. Ding, M.; Fratiglioni, L.; Johnell, K.; Santoni, G.; Fastbom, J.; Ljungman, P.; Marengoni, A.; Qiu, C. Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study. *Neurology* **2018**, *91*, e1732–e1740. [[CrossRef](#)]
35. Hamel, E.; Royea, J.; Ongali, B.; Tong, X.K. Neurovascular and cognitive failure in Alzheimer's disease: Benefits of cardiovascular therapy. *Cell Mol. Neurobiol.* **2016**, *36*, 219–232. [[CrossRef](#)] [[PubMed](#)]
36. Larsson, S.C.; Markus, H.S. Does treating vascular risk factors prevent dementia and Alzheimer's disease? a systematic review and meta-analysis. *J. Alzheimers Dis.* **2018**, *64*, 657–668. [[CrossRef](#)] [[PubMed](#)]
37. Loera-Valencia, R.; Goikolea, J.; Parrado-Fernandez, C.; Merino-Serrais, P.; Maioli, S. Alterations in cholesterol metabolism as a risk factor for developing Alzheimer's disease: Potential novel targets for treatment. *J. Steroid Biochem. Mol. Biol.* **2019**, *190*, 104–114. [[CrossRef](#)] [[PubMed](#)]
38. Hernandorena, I.; Duron, E.; Vidal, J.S.; Hanon, O. Treatment options and considerations for hypertensive patients to prevent dementia. *Expert Opin. Pharm.* **2017**, *18*, 989–1000. [[CrossRef](#)]
39. Marfany, A.; Sierra, C.; Camafort, M.; Doménech, M.; Coca, A. High blood pressure, Alzheimer disease and antihypertensive treatment. *Panminerva. Med.* **2018**, *60*, 8–16. [[CrossRef](#)]
40. Ye, R.; Hu, Y.; Yao, A.; Yang, Y.; Shi, Y.; Jiang, Y.; Zhang, J. Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: A meta-analysis. *Int. J. Clin. Pr.* **2015**, *69*, 674–681. [[CrossRef](#)]
41. Merlo, S.; Spampinato, S.F.; Sortino, M.A. Estrogen and Alzheimer's disease: Still an attractive topic despite disappointment from early clinical results. *Eur. J. Pharm.* **2017**, *817*, 51–58. [[CrossRef](#)]
42. Henderson, V.W. Alzheimer's disease: Review of hormone therapy trials and implications for treatment and prevention after menopause. *J. Steroid Biochem. Mol. Biol.* **2014**, *142*, 99–106. [[CrossRef](#)]
43. Fink, H.A.; Jutkowitz, E.; McCarten, J.R.; Hemmy, L.S.; Butler, M.; Davila, H.; Ratner, E.; Calvert, C.; Barclay, T.R.; Brasure, M.; et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: A systematic review. *Ann. Intern. Med.* **2018**, *168*, 39–51. [[CrossRef](#)]

44. Guardia-Laguarta, C.; Pera, M.; Lleó, A. gamma-secretase as a therapeutic target in Alzheimer's disease. *Curr. Drug Targets* **2010**, *11*, 506–517. [[CrossRef](#)]
45. Panza, F.; Frisardi, V.; Solfrizzi, V.; Imbimbo, B.; Logroscino, G.; Santamato, A.; Greco, A.; Seripa, D.; Pilotto, A. Interacting with  $\gamma$ -secretase for treating Alzheimer's disease: From inhibition to modulation. *Curr. Med. Chem.* **2011**, *18*, 5430–5447. [[CrossRef](#)] [[PubMed](#)]
46. Crump, C.J.; Johnson, D.S.; Li, Y.M. Development and mechanism of  $\gamma$ -secretase modulators for Alzheimer's disease. *Biochemistry* **2013**, *52*, 3197–3216. [[CrossRef](#)] [[PubMed](#)]
47. Siti, H.N.; Kamisah, Y.; Kamsiah, J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). *Vasc. Pharm.* **2015**, *71*, 40–56. [[CrossRef](#)] [[PubMed](#)]
48. Steven, S.; Münzel, T.; Daiber, A. Exploiting the pleiotropic antioxidant effects of established drugs in cardiovascular disease. *Int. J. Mol. Sci.* **2015**, *16*, 18185–18223. [[CrossRef](#)]
49. Silva, I.V.G.; de Figueiredo, R.C.; Rios, D.R.A. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. *Int. J. Mol. Sci.* **2019**, *20*, 3458. [[CrossRef](#)]
50. Anastasio, T.J. Exploring the correlation between the cognitive benefits of drug combinations in a clinical database and the efficacies of the same drug combinations predicted from a computational model. *J. Alzheimers Dis.* **2019**, *70*, 287–302. [[CrossRef](#)]
51. Anastasio, T.J. Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease. *Front. Pharm.* **2015**, *6*, 116. [[CrossRef](#)]
52. Anastasio, T.J. Exploring the contribution of estrogen to amyloid-Beta regulation: A novel multifactorial computational modeling approach. *Front. Pharm.* **2013**, *4*, 16. [[CrossRef](#)]